Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · Real-Time Price · USD
3.180
+0.020 (0.63%)
At close: Jul 25, 2025, 4:00 PM
3.190
+0.010 (0.31%)
After-hours: Jul 25, 2025, 5:17 PM EDT

Company Description

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States.

The company’s lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies.

It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins.

Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.

Compass Therapeutics, Inc.
Compass Therapeutics logo
CountryUnited States
Founded2014
IndustryBiotechnology
SectorHealthcare
Employees35
CEOThomas Schuetz

Contact Details

Address:
80 Guest Street, Suite 601
Boston, Massachusetts 02135
United States
Phone617 500 8099
Websitecompasstherapeutics.com

Stock Details

Ticker SymbolCMPX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001738021
CUSIP Number20454B104
ISIN NumberUS20454B1044
SIC Code2836

Key Executives

NamePosition
Dr. Thomas J. Schuetz M.D., Ph.D.Chief Executive Officer and Vice Chairman
Barry Shin J.D., M.B.A.Chief Financial Officer
Jonathan E. Anderman J.D.Senior Vice President, General Counsel and Corporate Secretary
Vered Bisker-Leib MBA, Ph.D.Advisor
Neil L. Lerner CPASenior Vice President and Chief Accounting Officer
Anna GiffordCommunications Manager
Dr. Minori Rosales M.D., Ph.D.Senior Vice President and Head of Clinical Development
Karin Herrera B.A.Senior Vice President and Head of Clinical Operations
Dr. James Kranz Ph.D.Vice President and Head of Chemistry Manufacturing and Controls

Latest SEC Filings

DateTypeTitle
Jul 16, 2025SCHEDULE 13G/AFiling
Jun 12, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 8, 202510-QQuarterly Report
May 8, 20258-KCurrent Report
Apr 29, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2025ARSFiling
Apr 29, 2025DEF 14AOther definitive proxy statements
Apr 11, 2025SCHEDULE 13D/AFiling
Apr 9, 2025144Filing